‹ ›
MYP_058737
← PREVIOUS NEXT → BACK
Basic Information
EK1
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor cross
Standard
36 amino acids
C196H317N43O64S
Standard
Sequence
SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKEL
Physicochemical Analysis
4331.93 Da
4.36
-5.52
-5.76
-0.1534
-0.43
0.75
-0.05
22.73
119.17
0.0833
2980.00
2980.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1772.25
-9.98
59.0
60.0
156.0
304.0
3.0
37.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0412122 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
PEG4-C(Palm)
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
Virus
PaperInhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion PMID32231345 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32231345/
RECORD: Rec_0414553 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
PEG8-K(Chol)
PEG8-K(Chol)
Bio-Activity Profile
Antiviral Anti-HCoV-229E Fusion inhibition
HCoV-229E | Huh-7 cells
0.5033±0.0209 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperSARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. | Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y. | Signal Transduct Target Ther. 2021 Aug 3;6(1):294. | DOI:10.1038/s41392-021-00698-x | PMID:34344868 PMID34344868 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34344868/
RECORD: Rec_0414664 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-SARS-CoV-2 Fusion inhibition
SARS-CoV-2 D614G | of cell; -cell
0.3146 μM
IC50
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperPeptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. | Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S. | Cell Res. 2022 Apr;32(4):404-406. | DOI:10.1038/s41422-022-00617-x | PMID:35087243 PMID35087243 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/35087243/
RECORD: Rec_0420547 VERIFIED: YES
Provenance & Taxonomy
Human coronavirus OC43 [Virus]
HR2-derived fusion inhibitor
31631
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
Severe acute respiratory syndrome coronavirus
1 μM
IC90
PaperInhibition of coronavirus entry in vitro and ex vivo by a lipid-conjugated peptide derived from the SARS-CoV-2 spike glycoprotein HRC domain PMID33082259 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/33082259/
RECORD: Rec_0425875 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
PEG8-K(Chol)
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
Virus
PMID34344868 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34344868/
FIRST PREV 1 ... 29 30 31 32 NEXT LAST
Showing 5 records on this page · Page 31 of 32